MaxCyte, Inc. — Q2 2022 Form 10-Q Summary
Business context and reporting period
MaxCyte is a commercial cell-engineering and life-sciences company providing Flow Electroporation-based instruments, processing assemblies, consumables, licenses and related services for cell therapy, drug discovery and biomanufacturing. The filing covers the three and six months ended June 30, 2022; results are unaudited. MaxCyte remains an emerging growth company and reported 101.7 million common shares outstanding as of August 2, 2022.
Financial performance and liquidity
| Metric | Three months ended June 30, 2022 | Prior-year period | Six months ended June 30, 2022 | Prior-year period |
|---|---|---|---|---|
| Revenue | $9.6 million | $7.1 million | $21.2 million | $13.6 million |
| Gross profit | $8.5 million | $6.3 million | $19.0 million | $12.1 million |
| Gross margin | 88% | 89% | 90% | 89% |
| Operating loss | $8.7 million | $4.4 million | $12.9 million | $10.8 million |
| Net loss | $8.3 million | $4.4 million | $12.3 million | $11.5 million |
| Net loss per share | $0.08 | $0.05 | $0.12 | $0.14 |
- Six-month revenue increased 56%, driven by cell therapy revenue of $15.1 million, drug discovery revenue of $4.1 million and program-related revenue of $2.0 million.
- Second-quarter revenue increased 35%; cell therapy revenue rose 61%, while program-related revenue declined to $0.04 million from $0.5 million because milestone timing is variable.
- Six-month operating expenses were $31.9 million, including research and development of $8.5 million, sales and marketing of $8.8 million, general and administrative expense of $13.7 million, and depreciation and amortization of $0.9 million.
- Stock-based compensation was $5.4 million for the six months, with $34.6 million of unrecognized compensation expense remaining at June 30, 2022.
- Cash used in operating activities was $2.8 million for the six months, compared with $9.0 million in the prior-year period. Capital expenditures were $12.8 million, primarily related to headquarters, laboratory and manufacturing infrastructure.
- Cash and cash equivalents were $109.2 million and short-term investments were $131.7 million at June 30, 2022, for combined liquidity of $240.9 million.
- The company had no indebtedness at June 30, 2022. Operating lease liabilities totaled $14.5 million, and total undiscounted lease payments for commenced leases were $25.0 million.
Material changes versus the prior comparable period
- Revenue growth was led by higher instrument and license revenue and increased disposable sales as cell therapy customers advanced development programs.
- Gross margin was broadly stable excluding program-related revenue; the six-month margin benefited from milestone revenue with no associated cost of goods sold, while the second-quarter margin declined slightly because of lower milestone revenue.
- Operating losses widened despite revenue growth because total operating expenses increased 39% for the six months. Sales and marketing increased 54% and general and administrative expense increased 88%, reflecting higher headcount, commercial expansion, public-company costs, insurance, legal expenses and occupancy costs.
- Research and development expense declined 9% for the six months primarily because CARMA platform wind-down costs were substantially lower; this was partly offset by higher compensation, stock-based compensation, laboratory and product-development costs.
- Interest and other expense fell to zero after repayment of the MidCap loan in March 2021 and settlement of the related warrant in August 2021. Interest income increased to $0.6 million for the six months because of higher invested cash following the 2021 IPO.
- Property and equipment, net increased to $20.6 million from $7.7 million at December 31, 2021, while inventory increased to $7.7 million from $5.2 million.
Guidance, outlook, commentary and risks
- Management expects revenue to increase over time as cell therapy programs progress, new customers emerge, the installed base under cell therapy licenses expands and additional Strategic Platform License agreements are signed. No quantitative revenue or earnings guidance was provided.
- Management expects continued net losses and higher operating expenses as it expands sales, field-application support, manufacturing capacity, research and development, product offerings and public-company infrastructure.
- Management stated that existing cash, cash equivalents and short-term investments are expected to fund operating and capital requirements for the foreseeable future, but acknowledged that actual cash use could exceed current expectations and additional financing may eventually be required.
- Management signed an SPL with Intima Bioscience during the first quarter of 2022 and reported signing an SPL with LG Chem in July 2022. Timing and amount of future milestone and sales-based payments remain uncertain.
- COVID-19 may continue to disrupt manufacturing, supply chains, customer operations, installations, demonstrations, travel and clinical development timelines. The filing states that its future financial impact cannot be quantified.
- Revenue is concentrated: one customer represented 25% of second-quarter revenue and 29% of six-month revenue. Two customers represented 45% of accounts receivable at June 30, 2022.
- The company relies on single-source or limited-source suppliers for certain components and purchased 32% of inventory during the six months from one supplier.
- Principal risks include continued losses, dependence on a limited product portfolio and partners, uncertain customer adoption, milestone variability, competition, supply constraints, product-development and regulatory risk, potential capital needs, and execution risk associated with scaling operations.
- The company reported no material legal proceedings and no material changes to the risk factors disclosed in its 2021 Form 10-K. Disclosure controls and procedures were evaluated as effective as of June 30, 2022.
Important facts for investors to verify
- Whether revenue growth and gross margins can continue without relying disproportionately on episodic SPL milestone payments.
- The timing, commercial potential and contractual economics of additional SPL agreements, including the LG Chem relationship.
- Customer and partner concentration, including the effect of losing a major customer or delayed clinical milestones.
- Cash-burn trends and whether $240.9 million of cash and short-term investments remains sufficient as operating expenses and capital spending increase.
- Progress in completing and utilizing the new headquarters, laboratory and manufacturing facilities and the related $29.6 million of incremental non-cancellable lease payments.
- Availability and pricing of critical components, inventory growth and the company’s ability to scale processing-assembly manufacturing.
- The effect of stock-based compensation, public-company costs and headcount expansion on future operating losses and share dilution.